Projektbeschreibung
Ein Impfstoff gegen Bauchspeicheldrüsenkrebs
Unser Immunsystem ist extrem gut darin, infizierte oder abnormale Zellen wie Krebszellen, die „fremde“ Antigene exprimieren, zu erkennen und abzutöten. Doch Krebs ist dafür bekannt, das Immunsystem durch verschiedene Strategien auszuhebeln. Das EU-finanzierte Projekt PAVE konzentriert sich auf das duktale Adenokarzinom des Pankreas (PDAC), eine der aggressivsten und tödlichsten Krebsarten, und will einen Impfstoff entwickeln, um das Immunsystem gegen diese Krankheit zu stärken oder zu reaktivieren. Diese Impfstoffe sollen die Einschränkungen durch die Mikroumgebung des Tumors und die geringe Anzahl tumorinfiltrierender Immunzellen überwinden. Darüber hinaus gehen die Forschenden auf die kürzliche Entdeckung ein, dass PDAC das Immunsystem ausnutzen, um ihr Wachstum zu stärken.
Ziel
A Nanovaccine Approach For The Treatment of Pancreatic Cancer By Multicomponent Immuno-Modulation: Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer deaths in men and women and still fatal in over 90% of patients. It is characterised by its extremely aggressive nature where it is also responsible for the highest mortality rate compared to other major cancers, resulting in excess of 250,000 deaths worldwide per annum. Current state-of-art therapies for advanced PDAC including chemo- and/or radiotherapy, despite extensive efforts, have met with only limited success.
Surgery is only applicable for those with early stages of the disease, or to relieve symptoms, if the cancer is blocking the bile duct or the bowel. There are two major reasons for the resistance of PDAC to conventional therapy. Firstly, PDAC has a very defining hallmark, where an abundance of stromal content is present in the tumour microenvironment (TME) to form a physical and biochemical barrier. Secondly, during progression of the disease, the body's immune system is hijacked to support the proliferation of the cancer. New approaches, such as immunotherapy, are therefore needed where it has already shown promise in overcoming many aspects of this resistance. Immunotherapy has the potential to treat minimal residual disease after pancreatic resection (surgery) as well as for metastatic and non-resectable PDAC. Our objective for this project
is to bring together a multidisciplinary and intersectoral group to develop novel vaccine approaches, including use of multiple immunomodulating components.
Wissenschaftliches Gebiet
Schlüsselbegriffe
Programm/Programme
Thema/Themen
Aufforderung zur Vorschlagseinreichung
Andere Projekte für diesen Aufruf anzeigenFinanzierungsplan
MSCA-ITN - Marie Skłodowska-Curie Innovative Training Networks (ITN)Koordinator
80539 Munchen
Deutschland